Yaacov Yanay - Pluristem CEO Pres

PSTI Stock  ILS 1,638  11.00  0.67%   

Insider

Yaacov Yanay is CEO Pres of Pluristem
Age 52
Phone972 7 4710 8600
Webhttps://pluri-biotech.com/

Pluristem Management Efficiency

The company has return on total asset (ROA) of (0.3735) % which means that it has lost $0.3735 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.8655) %, meaning that it generated substantial loss on money invested by shareholders. Pluristem's management efficiency ratios could be used to measure how well Pluristem manages its routine affairs as well as how well it operates its assets and liabilities.
Pluristem has accumulated 23.85 M in total debt. Pluristem has a current ratio of 1.57, which is within standard range for the sector. Debt can assist Pluristem until it has trouble settling it off, either with new capital or with free cash flow. So, Pluristem's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Pluristem sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Pluristem to invest in growth at high rates of return. When we think about Pluristem's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Hanni NehemanKamada
53
Jon KnightKamada
N/A
Jerry NealTower Semiconductor
74
Dani AshkenaziTower Semiconductor
60
Rami MyersonElbit Systems
N/A
Iris AvnerTower Semiconductor
54
Shiri NederNice
47
Yoav CheloucheTower Semiconductor
66
Haim DelmarElbit Systems
49
Yaacov KaganElbit Systems
N/A
Ari ShamissKamada
N/A
Bilha ShapiraElbit Systems
66
Noit LevyKaroubiTower Semiconductor
38
Yifat EsqKamada
46
Eran NirKamada
50
Lilach TopilskyKamada
N/A
Ariella RabanKamada
47
Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel. PLURISTEM THERAPEU operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 172 people. Pluristem (PSTI) is traded on Tel Aviv Stock Exchange in Israel and employs 153 people.

Management Performance

Pluristem Leadership Team

Elected by the shareholders, the Pluristem's board of directors comprises two types of representatives: Pluristem inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pluristem. The board's role is to monitor Pluristem's management team and ensure that shareholders' interests are well served. Pluristem's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pluristem's outside directors are responsible for providing unbiased perspectives on the board's policies.
Lior Raviv, Chief Officer
Nimrod Zvi, Chief Officer
Efrat LivneHadass, VP HR
Yaacov Yanay, CEO Pres
Chen FrancoYehuda, CFO, Treasurer, Secretary
Nitsan MD, Chief Officer

Pluristem Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pluristem a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Pluristem Stock

Pluristem financial ratios help investors to determine whether Pluristem Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pluristem with respect to the benefits of owning Pluristem security.